Delphine BADINAND
MD
-
Onco-radiotherapist at the Timone Hospital
APHM
MI is a diamond of the new Metropolis, offering a unique opportunity to drive science forward and provide more effective therapeutic options for our cancer patients.
Cancerology is booming and immunotherapy represents the most promising approach. At the APHM we have been at the forefront of these therapeutic advances and as a radiotherapist, I’m developing new strategies combining radiotherapy and immunotherapy to reach the « abscopal effect ». MI is a diamond of the new Metropolis, offering a unique opportunity to drive science forward and provide more effective therapeutic options for our cancer patients.
#cliniqueHave a look on our testimonies
With MI-mAbs and other cluster platforms, CIPHE is somewhat the "technology back office" of Marseille Immunopole.
Bernard MALISSEN
CIPHE, CIML
Each year, a large number of clinical trials are conducted by APHM clinicians alone or in partnership with industry players in biopharmaceuticals.
Frédéric VELY
AMU, AP-HM, CIML
Diagnostic in immuno-oncology is an innovative field combining the latest discoveries in immunology and new imaging technologies, such as digital pathology.
Fabienne HERMITTE
HalioDx
MI both accelerates research and development in immuno-oncology and offers cancer patients more options in terms of diagnostics and treatments, as well as more innovative clinical trials.
Fabrice BARLESI
AMU, Gustave Roussy, The Pioneer Project
your commitment to MI